Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCommerzbank Aktiengesellschaft /fi
Latest Disclosed Ownership7,281 shares
Latest Disclosed Value $ 3,251
Commerzbank Aktiengesellschaft /fi ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Commerzbank Aktiengesellschaft /fi filed a 13F-HR form disclosing ownership of 7,281 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $3,251,258 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 8,091 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -10.01% during the quarter. The current value of the position is $3,253,369 USD.

Commerzbank Aktiengesellschaft /fi has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,281 -810 -10.01 3 0.00 0.0680
2026-02-05 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,091 -484 -5.64 4 0.00 0.0746
2025-10-31 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,575 -1,275 -12.94 3 -25.00 0.0697
2025-07-24 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,850 8,069 453.06 4 0.1005
2025-05-02 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,781 0 0.00 1 0.0201
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,781 509 40.02 1 0.0171
2024-10-22 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,272 414 48.25 1 0.0158
2024-07-22 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 858 71 9.02 0 0.0133
2024-05-10 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 787 28 3.69 0 0.0109
2024-09-30 2023-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 759 759 0 0.0123
2024-02-01 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 759 759 0 0.0123
2024-10-03 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 -5,548 -100.00 0 -100.00
2024-10-03 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 0
2020-07-21 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -5,548 0
2024-10-03 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,548 -30,271 -84.51 1 -85.71 0.0590
2020-04-29 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,548 -30,271 1,320 0.0809
2024-10-03 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 35,819 -172,501 -82.81 8 -80.00 0.0764
2020-01-17 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 35,819 -172,501 7,843 0.0822
2024-10-03 2019-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 208,320 -884 -0.42 35 -7.89 0.2700
2019-10-17 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 208,320 -884 35,294 0.2870
2024-10-03 2019-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 209,204 -49,455 -19.12 38 -19.15 0.3036
2019-07-23 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 209,204 -49,455 38,364 0.2701
2024-10-03 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 258,659 -16,017 -5.83 48 4.44 0.4340
2019-05-13 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 258,659 -16,017 47,580 0.4806
2024-10-03 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 274,676 2,437 0.90 46 -13.46 0.4650
2019-02-06 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 274,676 2,437 45,517 0.4958
2024-10-04 2018-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 272,239 8,946 3.40 52 18.18 0.4547
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 272,239 8,946 52,471 0.4960
2024-10-04 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 263,293 1,872 45 0.4241
2024-10-04 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 263,293 1,872 0.72 45 4.76 0.4241
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 263,293 1,872 44,749 0.4571
2024-10-04 2018-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 261,421 4,063 1.58 43 10.53 0.4381
2018-05-01 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 261,421 4,063 42,606 0.4744
2024-10-04 2017-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 257,358 40,401 18.62 39 -99.88 0.4425
2018-01-26 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 257,358 40,401 38,568 0.4782
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 216,957 5,665 2.68 32,986 21.14 0.4345
2017-08-09 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 211,292 -14,284 -6.33 27,229 10.39 0.4572
2017-05-01 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 225,576 -32,681 -12.65 24,667 29.65 0.3652
2017-02-07 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 258,257 9,090 3.65 19,026 -12.44 0.2798
2016-11-10 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 249,167 3,759 1.53 21,730 2.94 0.3502
2016-08-01 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 245,408 20,958 9.34 21,110 18.32 0.1419
2016-05-10 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 224,450 -71,685 -24.21 17,842 -52.12 0.1496
2016-02-11 2015-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 296,135 4,242 1.45 37,263 22.58 0.2867
2016-02-05 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 296,135 37,263
2015-10-29 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 291,893 -50,868 -14.84 30,398 -28.18 0.2282
2015-08-10 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 342,761 18,227 5.62 42,324 10.55 0.2219
2015-05-01 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 324,534 324,534 0.00 38,285 0.2298
2015-02-05 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -466,692 -100.00 0 -100.00
2014-11-13 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 466,692 151,284 47.96 52,414 75.51 0.2113
2014-08-12 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 315,408 159,302 102.05 29,863 170.50 0.1526
2014-05-14 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 156,106 -11,659 -6.95 11,040 -16.74 0.0476
2014-02-13 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 167,765 -266,602 -61.38 13,260 -59.74 0.0649
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 434,367 374,283 622.93 32,934 584.70 0.1647
2013-07-23 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 60,084 60,084 4,810 0.0212
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2014-11-13 2014-09-30 13F VERTEX PHARMACEUTICALS CALL Call 0 -100.00 0 -100.00 n/a n/a n/a
2014-08-12 2014-06-30 13F VERTEX PHARMACEUTICALS CALL Call 30,000 2,840 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.